Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Medical Law Review
|
May 3, 2026
The promise of the EU's draft repurposing programme
Gabriela Lenarczyk, Johnathon Liddicoat
Journal of Law and the Biosciences
|
October 7, 2021
An empirical study of large, human biobanks: intellectual property policies and financial conditions for access
Matthew Jordan, Johnathon Liddicoat, Kathleen Liddell
Nature Biotechnology
|
April 8, 2015
Are the gene-patent storm clouds dissipating? A global snapshot
Johnathon Liddicoat, Tess Whitton, Dianne Nicol
Nature Biotechnology
|
November 9, 2016
Myriad's impact on gene patents
Mateo Aboy, Kathleen Liddell, Johnathon Liddicoat, et al.
Nature Biotechnology
|
December 7, 2018
Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?
Mateo Aboy, Cristina Crespo, Kathleen Liddell, et al.
Nature Biotechnology
|
April 14, 2022
European patent protection for medical uses of known products and drug repurposing
Mateo Aboy, Kathleen Liddell, Matthew Jordan, et al.
Nature Biotechnology
|
November 10, 2021
Mapping the European patent landscape for medical uses of known products
Mateo Aboy, Kathleen Liddell, Johnathon Liddicoat, et al.
Nature Biotechnology
|
September 13, 2017
After Myriad, what makes a gene patent claim 'markedly different' from nature?
Mateo Aboy, Johnathon Liddicoat, Kathleen Liddell, et al.
Nature Biotechnology
|
May 5, 2019
Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine
Mateo Aboy, Cristina Crespo, Kathleen Liddell, et al.
Nature Biotechnology
|
March 11, 2020
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
Mateo Aboy, Cristina Crespo, Kathleen Liddell, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Medical Law Review
|
May 3, 2026
The promise of the EU's draft repurposing programme
Gabriela Lenarczyk, Johnathon Liddicoat
Journal of Law and the Biosciences
|
October 7, 2021
An empirical study of large, human biobanks: intellectual property policies and financial conditions for access
Matthew Jordan, Johnathon Liddicoat, Kathleen Liddell
Nature Biotechnology
|
April 8, 2015
Are the gene-patent storm clouds dissipating? A global snapshot
Johnathon Liddicoat, Tess Whitton, Dianne Nicol
Nature Biotechnology
|
November 9, 2016
Myriad's impact on gene patents
Mateo Aboy, Kathleen Liddell, Johnathon Liddicoat, et al.
Nature Biotechnology
|
December 7, 2018
Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?
Mateo Aboy, Cristina Crespo, Kathleen Liddell, et al.
Nature Biotechnology
|
April 14, 2022
European patent protection for medical uses of known products and drug repurposing
Mateo Aboy, Kathleen Liddell, Matthew Jordan, et al.
Nature Biotechnology
|
November 10, 2021
Mapping the European patent landscape for medical uses of known products
Mateo Aboy, Kathleen Liddell, Johnathon Liddicoat, et al.
Nature Biotechnology
|
September 13, 2017
After Myriad, what makes a gene patent claim 'markedly different' from nature?
Mateo Aboy, Johnathon Liddicoat, Kathleen Liddell, et al.
Nature Biotechnology
|
May 5, 2019
Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine
Mateo Aboy, Cristina Crespo, Kathleen Liddell, et al.
Nature Biotechnology
|
March 11, 2020
One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?
Mateo Aboy, Cristina Crespo, Kathleen Liddell, et al.
Page
of 2